Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ASPH | Q12797 | 2/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765070 | 0.86 | CSNK2A1 (0.40) | TDP1POLBCA12CA9CSNK2A1 | |
| SCHEMBL23112014 | 0.86 | CSNK2A1 (0.40) | TDP1POLBCA12CA9CSNK2A1 | |
| SCHEMBL16041005 | 0.83 | SMN1; SMN2 (0.49) | TDP1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL7042463 | 0.81 | CA12 (0.57) | TDP1POLBCA12CA1CA2 | |
| SCHEMBL27032969 | 0.80 | POLB (0.43) | TDP1POLBCA12CA1CA2 | |
| SCHEMBL30639556 | 0.80 | POLB (0.43) | TDP1POLBCA12CA1CA2 | |
| SCHEMBL12794738 | 0.80 | POLB (0.43) | TDP1POLBCA12CA1CA2 | |
| SCHEMBL1044983 | 0.79 | TDP1 (0.42) | TDP1POLBCA12CA1CA2 | |
| SCHEMBL30989945 | 0.79 | ALDH1A1 (0.53) | TDP1POLBCA12CA1CA2 | |
| SCHEMBL23970774 | 0.79 | ALDH1A1 (0.53) | TDP1POLBCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12331029-B2 | Orexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-06-17 | — | — | US | disclosed |
| WO-2020120994-A1 | OREXIN 1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020120994-A1 | OREXIN 1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-18 | — | — | WO | disclosed |
| CN-110520423-A | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO | 2019-11-29 | — | — | CN | disclosed |
| CN-110036009-A | Substituted pyrrolidines and their use in the treatment of cystic fibrosis | 艾伯维公司 | 2019-07-19 | — | — | CN | disclosed |
| CN-110035993-A | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | 艾伯维公司 | 2019-07-19 | — | — | CN | disclosed |
| CN-106687445-A | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | 维颂公司 | 2017-05-17 | — | — | CN | disclosed |
| CN-104447716-A | Modulators of CFTR | VERTEX PHARMA | 2015-03-25 | — | — | CN | disclosed |
| CN-102762548-B | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMA | 2014-11-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | CNR1, CNR2, OPRM1 | TDP1 1579/4885POLB 4670/4885CA12 1803/4885 |
| US-12331029-B2 | Orexin 1 receptor antagonists | HCRTR1, HCRTR2, NPY1R | TDP1 4237/4885POLB 4802/4885CA12 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.